The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists.
作者信息
Cappello Maria, Busacca Anita, Guida Laura
机构信息
Gastroenterology & Hepatology Section, Promise, University of Palermo, Palermo, Italy.
出版信息
Gastroenterology. 2021 Apr;160(5):1885-1886. doi: 10.1053/j.gastro.2020.06.087. Epub 2020 Jul 6.
Abstract
摘要
相似文献
1
The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists.炎症性肠病中新冠病毒病的病程：肿瘤坏死因子拮抗剂的保护作用
Gastroenterology. 2021 Apr;160(5):1885-1886. doi: 10.1053/j.gastro.2020.06.087. Epub 2020 Jul 6.
2
Aminosalicylates and COVID-19: Facts or Coincidences?氨基水杨酸盐与2019冠状病毒病：事实还是巧合？
Gastroenterology. 2021 Apr;160(5):1884-1885. doi: 10.1053/j.gastro.2020.05.092. Epub 2020 Jun 15.
3
Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic.2019冠状病毒病大流行期间炎症性肠病的治疗决策
Gastroenterology. 2021 Apr;160(5):1883-1884. doi: 10.1053/j.gastro.2020.05.083. Epub 2020 Jun 15.
4
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry.药物对炎症性肠病患者新冠病毒病结局的影响：来自一项国际登记处的6000多名患者的分析
Gastroenterology. 2022 Jan;162(1):316-319.e5. doi: 10.1053/j.gastro.2021.09.011. Epub 2021 Sep 14.
5
COVID-19 and IBD drugs: should we change anything at the moment?新冠病毒肺炎与炎症性肠病药物：我们目前是否应做出任何改变？
Gut. 2021 Apr;70(4):632-634. doi: 10.1136/gutjnl-2020-323247. Epub 2020 Nov 19.
6
Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19.炎症性肠病中的抗TNF-α药物与COVID-19病程
Inflamm Bowel Dis. 2020 Jun 18;26(7):e73. doi: 10.1093/ibd/izaa114.
7
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
8
Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.信：接受双重靶向治疗的两位炎症性肠病患者的 SARS-CoV-2 感染情况-作者答复。
Aliment Pharmacol Ther. 2021 Mar;53(6):766-767. doi: 10.1111/apt.16287.
9
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.信：两名接受双重靶向治疗的 IBD 患者感染 SARS-CoV-2。
Aliment Pharmacol Ther. 2021 Mar;53(6):764-765. doi: 10.1111/apt.16271.
10
Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.接受肿瘤坏死因子抑制剂治疗的幼年特发性关节炎患者接触了新冠病毒感染的家庭成员。
Semin Arthritis Rheum. 2020 Dec;50(6):1214-1215. doi: 10.1016/j.semarthrit.2020.09.012. Epub 2020 Oct 2.
引用本文的文献
1
Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry.与神经肌肉疾病患者 COVID-19 结局严重程度相关的因素：来自国际神经肌肉 COVID-19 注册中心的数据。
Eur J Neurol. 2023 Feb;30(2):399-412. doi: 10.1111/ene.15613. Epub 2022 Nov 18.
2
COVID-19 and corticosteroids: a narrative review.COVID-19 和皮质类固醇：叙述性综述。
Inflammopharmacology. 2022 Aug;30(4):1189-1205. doi: 10.1007/s10787-022-00987-z. Epub 2022 May 13.
3
Targeting TNF-α for COVID-19: Recent Advanced and Controversies.针对 COVID-19 的 TNF-α 靶点：最新进展与争议。
Front Public Health. 2022 Feb 11;10:833967. doi: 10.3389/fpubh.2022.833967. eCollection 2022.
4
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.炎症性肠病患者 COVID-19 的临床结局：一项全国性队列研究。
J Crohns Colitis. 2021 Apr 6;15(4):529-539. doi: 10.1093/ecco-jcc/jjaa215.
Zotero 插件